




PROTECTIVE EFFECT OF COMMIPHORA MUKUL GUM RESIN ON BRAIN IN STREPTOZOTOCIN-
INDUCED DIABETIC RATS 
 
SUDHAKARA G.1, RAMESH B.2, MALLAIAH P.1, MANJUNATHA B.3, DESIREDDY SARALAKUMARI1* 
1,2Department of Biochemistry, 3
 Received: 11 Jun 2015 Revised and Accepted: 27 Jul 2015 
Department of Zoology, Sri Krishnadevaraya University, Anantapuramu, Andhra Pradesh, India 
Email: skumari1@yahoo.co   
ABSTRACT 
Objective: The present study was undertaken to investigate the hypolipidemic activity of ethanolic extract of Commiphora mukul gum resin 
(EtCMGR) on the brain of streptozotocin (STZ) induced diabetic Wistar rats.  
Methods: Thirty two rats, included for the study, were divided into four groups: control (C), control treated with EtCMGR (C+CM), diabetic (D) and 
diabetic treated with EtCMGR (D+CM). Diabetes was induced by single intraperitonial injection of STZ (55 mg/kg b.w.).  
Results: Diabetic rats showed significant reduction in the levels of total lipids, phospholipids, cholesterol, glycolipids and protein level and 
significant decrease in the activity of acetylcholinesterase while the levels of triglycerides, acetylcholine and the activities of glutamate pyruvate 
transaminases (GPT) and glutamate oxaloacetate transaminases (GOT) increased significantly when compared to control group. Oral administration 
of EtCMGR (suspended in 5% Tween-80 in distilled water prior to use) daily at a concentration of 200 mg/kg b.w. to group-D+CM rats for 60 days 
reversed the above changes significantly.  
Conclusion: These results suggest that EtCMGR exhibits hypolipidemic effect in the STZ-induced diabetic rats. 
Keywords: Acetylcholinesterase, Commiphora mukul, Hypolipidemic activity, Streptozotocin. 
 
INTRODUCTION 
Diabetes induced in experimental animals by administration of 
drugs like STZ is a widely used model system with many correlations 
to insulin-dependent diabetes mellitus in humans [1]. This disorder 
is characterized by elevated blood glucose levels and metabolic 
abnormalities, resulting from decreased levels of circulating insulin 
to target organs, including the brain [2, 3]. Brain is the most 
sensitive organ susceptible to oxidative stress due to its great 
oxygen consumption, high lipid content and poor antioxidant 
defences. One of the mechanisms of diabetes enhanced brain injury 
is oxidative stress caused by hyperglycemia. High oxidative stress 
can lead to microvascular cerebral diseases, e. g., stroke, cerebral 
haemorrhage, and brain infraction [4, 5]. Under experimental 
conditions, hyperglycemia dramatically increases neuronal 
alterations and glial cell damage caused by temporary ischemia [6]. 
Free radical species impair the central nervous system, attacking 
neurons and Schwann cells and the peripheral nerves [7]. Because of 
their high poly unsaturated lipid content, Schwann cells and axons 
are particularly sensitive to oxygen free radical damage; lipid 
peroxidation may increase cell membrane rigidity and impair cell 
function. Lipid peroxidation of the neuronal membrane causes loss 
of membrane fluidity and inhibition of membrane linked enzymes, 
increased neurolipofuscin deposition leading to diminished 
neurotransmitter uptake and loss of membrane asymmetry [8, 9], 
but also affects the activities of various membrane-bound enzymes, 
including acetyl cholinesterase (AchE) and ATPases. Streptozotocin 
is a valuable agent for experimental induction of diabetes. Its 
diabetogenic effect is a direct result of irreversible damage to the 
pancreatic β-cells, resulting in degranulation and loss of insulin 
secretion [10]. Insulin has been shown to stimulate both glucose 
uptake by tissues and tissue protein synthesis [11]. The major 
source of energy in the brain is glucose and morbid changes in 
nerves lead to diabetes [12]. Insulin deficiency will result in 
decreased activity of lipoprotein lipase and increased mobilisation of 
free fatty acids from peripheral fat depots. The STZ induced diabetic 
animal is thus considered as an animal model of Type-I diabetes 
mellitus and hyperlipidemia [13]. Diabetes has also been associated 
with an increased risk for developing premature arteriosclerosis due 
to increase in triacylglyceroles and low density lipoproteins and 
decrease in light density lipoprotein levels [14]. Additionally, free 
radical scavengers have been shown to protect neurons against a 
variety of experimental neurodegenerative conditions [15], as well 
as attenuation of the oxidative stress and diabetic state induced by 
STZ [16, 17]. The brain is especially susceptible to free radical injury 
because of its elevated metabolic rate and rich lipid composition. 
Therefore, any toxicity on the brain can be predicted by evaluating 
antioxidant system and lipid peroxidation [7]. 
Regions with greatest potential, where diabetes mellitus rates could 
rise to 2-3 fold than the present rates are Asia and Africa [18]. Many 
herbal medicines have been recommended for the treatment of 
diabetes [19, 20]. Plant drugs are frequently considered to be less 
toxic and more free from side effects than synthetic ones [21]. Many 
minor components of foods such as secondary plant metabolities 
have shown to alter biological processes, which may reduce the risk 
of chronic diseases in human such as diabetes mellitus and 
myocardial infarction [22].  
Commiphora mukul (C. mukul) (family Burseraceae) is indigenous to 
western India and has been in use as a valued herb in Ayurvedic 
medicine for over 2500 years. Gum guggul is the oleoresin of C. 
mukul, a plant that is native to India, and its extracts include 
compounds known for their hypolipidemic properties—the Z-and E-
isomers of guggulsterone and its related guggulsterols. Lipid 
lowering activity of guggul however, was first reported by Satyavati 
[23] which was further confirmed in many experimental models 
[24]. C. mukul has been used as an inactive pharmaceutical 
ingredient, binding agent, anti-obesity agent, and cholesterol-
reducing agent. The resin secreted by the plant C. mukul known as 
guggul is one of the widely used drugs in Ayurveda for the treatment 
of several disorders such as gout arthritis, rheumatism, 
atherosclerosis, ulcers and inflammation [25]. Early research 
looking at the effect of gugglesterone appeared to have positive 
effects. Studies, in both animal and humans demonstrated that 
guggul sterone may significantly lower blood lipid levels [26, 27] 
and may lower cholesterol levels [28, 29]. In addition, our earlier 
studies proved hypolipidemic activity of C. mukul seen in insulin 
deficient Wistar rats [30] and hypolipidemic activity of C. mukul in 
fructose fed Wistar rats [31]. The presence of strong antioxidant 
principles in C. mukul thus prompted us to design the present study 
to investigate whether management with C. mukul has any 
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protective effect on brain lipids and activities of transaminases and 
acetyl cholinesterase in STZ induced diabetic rats. 
MATERIALS AND METHODS 
Chemicals 
STZ was obtained from the Sigma (St. Louis, MO, USA) and 2,4-dinitro 
phenyl hydrazine (DNPH) was procured from Sd-Fine Chemical, India. 
All other chemicals and solvents of analytical grade were procured 
from Sisco Research Laboratories Ltd., Mumbai, India. 
Collection of plant material 
EtCMGR (brown, dry powder, and cream colour) was purchased 
from Chemiloids (manufactures and exporters of herbal extracts) 
Vijayawada, Andhra Pradesh, India. Herb to product ratio was 8:1 
and the extract was suspended in 5% Tween-80 in distilled water 
prior to use. 
Induction of diabetes  
Two-three week-old male Wistar rats of body weight 125–150 g 
procured from Sri Raghavendra Enterprises (Bangalore, India), were 
acclimatized for 7 days to our animal house, and maintained at 
standard conditions of temperature and relative humidity, with a 12 
h light/dark cycle. Water and commercial rat feed were provided ad 
libitum. The current work was carried out with a prior permission 
from our institutional animal ethical committee (Regd. no. 
470/01/a/CPCSEA, dt. 24th August 2001). Diabetes was induced in 
overnight fasted rats by a single intraperitoneal injection of freshly 
prepared STZ solution (55 mg/kg b.w., in ice cold 0.1 M citrate 
buffer, pH 4.5 in a volume of 0.1 ml per rat). After 72 h of STZ 
administration, the plasma glucose level of each rat was determined 
for confirmation of diabetes. Rats with plasma glucose level above 
250 mg/dl were considered as diabetic and used in the experiment. 
Experimental design 
In the present experiment, a total of 32 rats (16 diabetic rats; 16 
normal rats) were used. The rats were divided into four groups of 8 
each: control (C); control rats treated with EtCMGR (C+CM); diabetic 
(D); and diabetic rats treated with EtCMGR (D+CM). The dose of 
EtCMGR in the current study is based on the earlier reports on the 
extract [32]. Diabetic treated group and control treated groups 
received EtCMGR (2 ml of 5% Tween-80) by orogastric tube at a 
dose of 200 mg/kg b.w. for 60 days, whereas, 2 ml of distilled water 
was administered to control and diabetic rats. Based on results of 
the preliminary experiment on dose-dependent antihyperlipidemic 
effect of EtCMGR, a dose less than 200 mg/kg b.w. was not expected 
to be effective in rats [32].  
Animal sacrifice and organ collection 
After the experimental period of 60 days, the animals from each 
experimental group were starved for 12 h and sacrificed by cervical 
dislocation and immediately the whole brain was dissected out and 
washed with ice-cold saline and used for analysis. 
Extraction of lipids from brain tissue 
Tissue (250 mg) homogenate was prepared in Folch reagent (2:1 
chloroform-methanol) using Potter-Elvehjem homogenizer and 
centrifuged at 3000 rpm. Five ml of the supernatant was mixed with 
3 ml of distilled water and again centrifuged at 3000 rpm and 
resulting organic phase was used for total lipids, triglycerides, 
cholesterol, phospholipids and glycolipids analysis by the method of 
Folch et al. [33]. Total lipids were estimated by gravimetric method. 
Estimation of triglycerides 
Triglycerides (TG) were estimated by GPO-PAP enzymatic method 
using Liquid Gold Diagnostic kit according to the method of Foosati 
et al. [34]. Sixty µl of the lipid extract, taken in an eppendorf tube, 
was allowed to evaporate in an incubator. To this 1.0 ml of the 
triglyceride reagent was added, mixed and incubated at 37 ˚C for 10 
min. Triglyceride standard (200 mg%) and water blank were also 
treated in a similar manner. After incubation, absorbance was read 
at 505 nm and values are expressed as mg/g tissue. 
Estimation of cholesterol 
Total cholesterol was estimated by CHOD-PAP enzymatic method 
using Liquid Gold Diagnostic kit [35]. Sixty µl of lipid extract, taken 
in an eppendorf tube, was allowed to evaporate in an incubator. To 
this 1.0 ml of the cholesterol reagent was added, mixed and 
incubated at 37 ̊ C  for 10 min. Cholesterol standard (200 mg%) and 
water blank were also treated in a similar manner. After incubation, 
absorbance was read at 510 nm and values are expressed as mg/g 
tissue. 
Estimation of phospholipids  
Phospholipids (PL) were estimated by the method of Connerty et al. 
[36]. Phospholipids were digested with H2SO4 and the liberated 
inorganic phosphate was estimated by the method of Fiske and 
Subbarow method [37]. Two hundrend µl of lipid extract sample was 
subjected to evaporation and 1 ml of 10 N H2SO4 was added and 
digested for 1 h in a boiling water bath. Then 20 µl of H2O2 was 
added and the solution was boiled until the liquid becomes 
colourless. The tubes were cooled and phosphorus was estimated by 
Fiske Subbarow method. To the above digest 1.0 ml of molybdate II, 
0.4 ml of ANSA (1-amino-2-napthol-4-sulfonic acid) reagents were 
added and the volume was made up to 10 ml with distilled water. 
After an incubation period of 15 min, the blue colour formed was 
read at 660 nm. The phospholipid content is calculated by 
multiplication of phosphate value by 25. The results are expressed 
as mg/g tissue.  
Estimation of glycolipids  
Glycolipids (GL) were estimated based on the method of Roughan 
and Batt [38]. Two hundrend µl of brain homogenate was subjected 
to evaporation and 2 ml of 2 N sulphuric acid was added and 
digested for 2 h in a boiling water bath. After hydrolysis, 4 ml of 
chloroform was added and centrifuged. The aqueous layer was 
separated and 50 µl of 80% phenol was added followed by 4 ml of 
concentrated H2SO4. The orange colour was measured at 480 nm. A 
series of galactose standards (20-200 µg) were treated in similar 
manner. Glycolipid concentration was estimated by multiplying 
galactose content with 4.45. The values are expressed as mg/g 
tissue. 
Preparation of brain homogenate for activities of enzymes 
(protein and acetyl choline and activities of acetylcholine 
esterase and transaminases) 
Ten per cent brain homogenate was prepared in 0.15 M potassium 
chloride by using Potter-Elvehjem homogenizer at 0 ˚C and 
centrifuged at 12,000 rpm for 45 min at 0-4 ˚C. The supernatant thus 
obtained was distributed into eppendorf tubes, labelled and stored 
at-20 ˚C and used for enzyme assays. 
Determination of protein content 
The protein content of tissue homogenates was determined by the 
Lowry protein assay using bovine serum albumin as the standard 
[39]. 
Estimation of acetyl choline  
Acetyl choline (Ach) content was estimated by the method of Metcalf 
[40] as described by Augustinson [41]. In this method the acetyl 
group reacts with alkaline hydroxylamine to form acetyl 
hydroxamate, which then reacts with ferric chloride in acidic 
medium to form a brown coloured complex which was measured 
spectrophotometrically at 540 nm against reagent blank. The acetyl 
choline content is expressed as µmoles of Ach/g of tissue. 
Estimation of Acetylcholinesterase activity 
The activity of Acetycholinesterase (AchE) was estimated by the 
method of Ellman et al. [42]. Thio-choline, released from acetyl thio-
choline by the action of enzyme, reacts with–SH group of DTNB (5, 
5’-Dithio-Bis (2-Nitrobenzoic Acid)) reducing it to thiol, which has 
maximum absorbance at 412 nm. The activity was calculated by 
using molar extinction coefficient of SH group of DTNB as 14.3x103 
and expressed as µmoles of Ach hydrolysed/min/mg protein. 
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Estimation of transaminases activities [(glutamate pyruvate 
transaminases (GPT) and glutamate oxaloacetate trans-
aminases (GOT)] 
Pyruvate gives a brown colored compound with 2, 4-Dinitrophenyl 
hydrazine (DNPH) which is measured chromatically at 520 nm [43]. 
The enzyme activities are expressed as µg of pyruvate 
liberated/min/mg protein. 
Statistical analysis 
The results were expressed as mean±SEM. for eight rats in each 
group. Data were analysed for significant difference using Duncan’s 
multiple range test (P<0.05) [44]. 
RESULTS  
Effect of EtCMGR on brain lipid profiles 
Table 1 represents data on total lipids constitute phospholipids, 
glycolipids, cholesterol, triglycerides and also the brain lipids profile of 
groups-C, C+CM, D and D+CM rats at the end of experimental period. STZ 
induced diabetic rats showed significant decrease in phospholipids, 
glycolipids, and cholesterol (29%, 72.5% and 25%) and significant 
increase intriglycerides (33.6%) when compared with group-C. 
EtCMGR treatment for 60 days caused significant increase in 
phospholipids, glycolipid, and cholesterol (12%, 114% and 16%) 
and significant decrease in triglycerides (22%) in group-D+CM rats 
when compared to group-D. But this significant increase in 
phospholipids, glycolipids, and cholesterol could not reach the 
control values whereas triglycerides levels were normalized. Thus 
phospholipids, glycolipids, and cholesterol levels (20%, 41% and 
13%) in group-D+CM rats were still significantly lower (25%, 40% 
and 14%) when compared to group-C whereas EtCMGR treatment 
for 60 days to group-C+CM rats showed slight increase in glycolipids 
(54 %) and decrease in cholesterol and phospholipids (10% and 
5%) and no significant change in triglycerides levels when compared 
to group-C. 
Effect of EtCMGR on acetylcholine and acetylcholine esterase 
Table 2 illustrates the concentration of Ach and the activity of AchE 
in the brain of four experimental groups. Diabetic group showed 
significant decrease in the activity of AchE (8%) and increase in Ach 
(29%) content when compared with group-C. EtCMGR treatment for 
60 days resulted in significant increase in the activity of AchE (40%) 
and significant decrease in Ach (48%) content in group-D+CM rats 
when compared to group-D. At 60 days, group-C+CM rats showed 
significantly higher activity of AchE (68%) and slight decrease in Ach 
(36%) content when compared to group-C. Thus, the present study 
indicates the protective effect of EtCMGR treatment in maintaining 
the normal level of neurotransmitter i.e., Ach even under STZ 
induced diabetic state. 
  
Table 1: Effect of EtCMGR administration on brain lipid profile in diabetic rats 
Experimental 
groups 










Group C 330.65±14.70d 64.80±1.42c 8.44±0.22a 32.52±0.97d 3.49±0.22c 
Group C+CM 300.21±6.27c 61.76±1.29c 7.63±0.32b 29.21±0.36c 4.39±0.27d 
Group D 135.16±15.76a 46.21±2.06a 11.28±0.24d 24.42±1.39a 0.96±0.11a 
Group D+CM 220.00±6.53b 51.69±1.53b 8.84±0.44c 28.31±0.80c 2.06±0.22b 
C: control, C+CM: control rats treated with EtCMGR, D: diabetic, D+CM: diabetic rats treated with EtCMGR. Values are expressed as mean±SEM (n=8 
animals). Means with different superscripts within the column are significantly different at P<0.05 (Duncan’s multiple range test). 
 
Table 2: Effect of EtCMGR administration on brain acetylcholine content and activity of acetylcholinesterase in diabetic rats 
Experimental groups Acetylcholinesterase (µmoles of Ach hydrolysed/min/mg protein) Acetylcholine (µmoles of Ach/g tissue) 
Group C 0.296±0.019a 3.59±0.17a 
Group C+CM 0.498±0.026d 2.28±0.11b 
Group D 0.274±0.009a 5.39±0.18c 
Group D+CM 0.382±0.023b 2.80±0.18b 
C: control, C+CM: control rats treated with EtCMGR, D: diabetic, D+CM: diabetic rats treated with EtCMGR. Values are expressed as mean±SEM (n=8 
animals). Means with different superscripts within the column are significantly different at P<0.05 (Duncan’s multiple range test). 
 
Table 3: Effect of EtCMGR administration on protein content and activities of transaminases in diabetic rats 
Experimental 
groups 
 Protein (mg/g 
tissue) 
 GPT (µg of Pyruvate formed/min/mg 
protein) 
 GOT (µg of Pyruvate formed/min/mg 
protein) 
Group C 28.11±0.79a 3.58±0.22a 2.89±0.20a 
Group C+CM 22.57±0.52b 3.50±0.16a 3.01±0.11b 
Group D 20.26±0.62d 4.45±0.07b 4.83±0.15d 
Group D+CM 23.88±0.70b 3.79±0.13b 3.53±0.11c 
C: control, C+CM: control rats treated EtCMGR, D: diabetic, D+CM: diabetic rats treated with EtCMGR. Values are expressed as mean±SEM (n=8 
animals). Means with different superscripts within the column are significantly different at P<0.05 (Duncan’s multiple range test). 
 
Effect of EtCMGR on transaminases 
Data presented in table 3 indicate total protein content and activities 
of transaminases (GOT and GPT) measured in the four experimental 
groups. STZ induced diabetic rats showed significant decrease in 
protein content (28%) with significantly increased activities of GOT 
(67%) and GPT (24%) in brain when compared with group-C. 
EtCMGR treatment for 60 days in group-D+CM rats resulted in 
significant increase in protein content (18%) with significantly 
decreased activities of GOT (27%) and GPT (15%) in brain 
compared to group-D. But this change in protein content and 
transaminases in group-D+CM rats could not reach the control 
values. However group-C+CM rats showed no significant variation in 
protein content and activities of GPT and GOT when compared to 
group-C. 
DISCUSSION 
Diabetes mellitus is a chronic disease which cannot be completely 
cured and may lead to development of complications if not properly 
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regulated. Diabetes is primarily characterized by hyperglycaemia 
which results from lack of insulin or a weak response of tissues to this 
hormone. It is associated with long-term complications affecting the 
eyes, kidneys, cardiovascular system and nervous system [45-47].  
In the current study, the significant decrease in total lipid content of 
group-D rats may be due to increased catabolism of lipids and/or 
enhanced LPO due to oxidative stress observed under diabetic 
conditions. Earlier studies in our laboratory demonstrated a 
defective metabolism of lipid peroxides in brain tissue of diabetic 
animals [48]. EtCMGR treatment for 60 days showed partial 
recovery from diabetic induced decrease in total lipid content of 
group-D+CM which may be due to its protective effect against 
diabetic induced alterations in lipid metabolism.  
In STZ induced diabetic rat brain alterations may be responsible for 
demyelization and nerve degeneration. The alterations in brain 
lipids lead to changes in physiological properties of membranes, in 
enzyme activities, receptors, transport, and cellular interactions and 
activities of membrane bound proteins [49]. These physiological 
changes are accompanied by learning and behavioural deficits in 
rats and mice [50, 51]. Brain is considered the richest organ of the 
body in cholesterol. It is an important constituent of brain and is 
used for membrane synthesis and for many other activities by cells 
through the body and phospholipids and glycolipids are essential 
components of myelin, microsomal and mitochondrial fractions of 
brain. It was suggested that a number of neurological and chemical 
changes occur in the brain tissue due to the decrease in cholesterol 
synthesis in the diabetes [52]. In our study, the cholesterol level 
decreased in the brain tissue of group-D rats. In contrast, its level 
was increased and close to the control group values as a result of the 
EtCMGR administration in the group-D+CM. The resulting increase 
in the level of the cholesterol can be caused by the protective effects 
of the EtCMGR on the neurological and metabolic changes in the 
brain tissue of diabetic rats. 
Acetylcholine is the primary neurotransmitter of the cholinergic 
system and its activity is regulated by acetylcholine esterase (AChE). 
Acetyl cholinesterase in brain is chiefly localized in neurons and 
belongs to a family of hydrolases. It hydrolyses acetylcholine and is 
used as a marker for cholinergic neural function. Degradation of 
acetylcholine is necessary to depolarize nerves so that it might 
repolarize in the next conduction event. The termination of nerve 
impulse transmission is accomplished through the degradation of 
acetylcholine into choline and acetyl CoA by AChE [58]. Significant 
decrease in the activity of AchE and increase in the content of 
acetylcholine was observed in the brain of group-D rats compared to 
group-C. The decreased AChE activity could be due to a decrease in 
the enzyme synthesis by the inhibitory action of the toxicants [59]. It 
was reported that AChE varies in different organisms responding to 
environmental stress [60]. Some studies suggested that rat brain 
AChE activity is not significantly altered by STZ [61, 62]. While some 
reports refer to reduced rat brain AChE activity occurs due to 
diabetes [63, 64]. Moreover, an increase in whole brain AChE 
activity due to diabetes. Our reports of increased concentration of 
Ach and decreased activity of AchE in diabetic rats are in agreement 
with earlier studies [65-67]. The increased activity of acetylcholine 
esterase by C. mukul treatment observed both in groups-D+CM and 
C+CM may be due to increased plasma insulin concentration and 
decreased blood glucose levels in group-D+CM compared to group-D 
and increased insulin sensitivity in group-C+CM. Similar to our 
studies it was demonstrated that decreased AchE activity in brain 
and heart can be reversed by insulin administration [68]. Thus 
restoration of Ach concentration and increased AchE activity in 
group-D+CM rats may be due to improved plasma insulin level by 
EtCMGR treatment. EtCMGR was reported to possess 
antihyperglycemic activity in STZ [48, 30] and fructose fed diabetic 
animals [31].  
The decreased phospholipids and 
glycolipids and increased triglyceride content of group-D rats 
compared to group-C rats indicate the presence of lipid damage or 
oxidation. Our reports of decreased phospholipids and cholesterol 
content in diabetic rats are in agreement with earlier studies [53] 
suggesting that membrane function may be altered and in addition 
to physicochemical alterations, the specific activities of several 
membrane bound enzymes (AchE, Mg 2+-ATPase, and Na+, K+-
ATPase) are significantly decreased and play a role in the 
development of diabetic complications in brain. Similar results were 
also reported with regard to the effect of morphine sulphate on 
brain [54]. Very few studies are available on the protective effect of 
plants on altered lipid components in diabetic animals. Guggulipid, 
an alkaloid of C. mukul [55], dried flowers of Adenocalymma 
alliaceum [56], Trigonella graceum [57]were reported to possess 
hypolipidemic activity in hypercholesterolaemic rats and in type 1 
diabetic animals. The present study is the first to demonstrate the 
neuroprotective effect of EtCMGR against diabetes induced lipid 
alterations in the brain of rats. 
Measurements of tissue transaminases are useful to assess the tissue 
functions. Their activities are related to protein metabolism and the 
maintenance of amino acid homeostasis and might be an indicator of 
mitochondrial injury [69]. Further, enhanced protein glycation and 
oxidative stress under hyperglycemic conditions indicates altered 
protein metabolism in diabetes. Increased GOT activity may be 
related to an increased transport of NADH from the cytosol to 
mitochondria [70]. Matthews et al. [71] reported that both the 
enzymes degrade glutamate; though only GPT was able to reduce 
toxic (500 µM) levels of glutamate into the physiologic (<20 µM) 
range. The excitotoxic effect of glutamate is believed to be the cause 
of several neurodegenerative processes [72] and several enzymes 
with the capacity to degrade glutamate have been suggested as 
possible neuro-protectants [71]. Thus, enhanced transaminase 
activities in group-D rats indicate an adaptive mechanism to 
decrease the glutamate level in the brain. Our reports of decrease in 
protein content and increase in extent of GPT and GOT activities are 
supported by earlier studies on diabetic rats [73]. This may be due 
to increased protein turnover and also increased catabolism of 
amino acid in the brain of diabetic rats due to enhanced protein 
oxidation and protein glycation observed under hyperglycemic 
conditions [48]. The partial rectification of decreased protein 
content and enhanced transaminases activities observed in group-
D+CM by EtCMGR treatment which may be due to its 
antihyperglycemic activity with enhanced insulin secretion. Thus C. 
mukul treatment to diabetic rats showed improved brain energy 
metabolism. 
CONCLUSION 
In summary, EtCMGR has been shown to have, besides hypoglycemic 
properties, strong hypolipidemic action on diabetic 
hypertriglyceridemia and hypercholestrolemic as well. This could be 
useful for prevention or early treatment of diabetic disorders.
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